Literature DB >> 22422139

Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies.

Yasvir A Tesiram1, Megan Lerner, Charles Stewart, Charity Njoku, Daniel J Brackett.   

Abstract

OBJECTIVES: The aims of this study were (1) to determine nuclear magnetic resonance spectroscopic characteristics and metabolite profiles of serum samples from patients with pancreatic cancer compared with noncancerous control samples and (2) to ascertain if the accuracy of metabolite identification by 1D spectra can be improved upon by confirmation of spin-system assignment using more sophisticated experiments.
METHODS: Nuclear magnetic resonance spectra, including 1D, total correlation spectroscopy, and heteronuclear multiple/single quantum coherence, were obtained from serum samples from patients with pancreatic cancer and control subjects and used to determine serum levels of a range of metabolites.
RESULTS: The data show that total choline (P = 0.03), taurine (P = 0.03), and glucose plus triglycerides (P = 0.01) are significantly higher in cancer versus control samples. Also detected were species that could not be individually identified and that were designated UCM (unresolved complex matter). Levels of UCM are significantly higher in subjects with cancer, being almost double those of control samples.
CONCLUSIONS: Although metabolites such as lactate, taurine, glucose, choline, and triglycerides can be determined from 1D spectra, accuracy is improved by confirmation of spin-system assignment with total correlation spectroscopy and heteronuclear multiple/single quantum coherence spectral analysis. In addition, we introduce a new metric, UCM, which is at higher concentrations in cancer compared with control samples.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422139     DOI: 10.1097/MPA.0b013e31822a708c

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

1.  Volatile Organic Compounds in Urine for Noninvasive Diagnosis of Malignant Biliary Strictures: A Pilot Study.

Authors:  Udayakumar Navaneethan; Mansour A Parsi; Dennisdhilak Lourdusamy; David Grove; Madhusudhan R Sanaka; Jeffrey P Hammel; John J Vargo; Raed A Dweik
Journal:  Dig Dis Sci       Date:  2015-02-24       Impact factor: 3.199

Review 2.  Metabolomics in pancreatic cancer biomarkers research.

Authors:  Jaroslav Tumas; Kotryna Kvederaviciute; Marius Petrulionis; Benediktas Kurlinkus; Arnas Rimkus; Greta Sakalauskaite; Jonas Cicenas; Audrius Sileikis
Journal:  Med Oncol       Date:  2016-11-02       Impact factor: 3.064

3.  A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women.

Authors:  Li Jiao; Suman Maity; Cristian Coarfa; Kimal Rajapakshe; Liang Chen; Feng Jin; Vasanta Putluri; Lesley F Tinker; Qianxing Mo; Fengju Chen; Subrata Sen; Haleh Sangi-Hyghpeykar; Hashem B El-Serag; Nagireddy Putluri
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-05

4.  Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma.

Authors:  Alexander Benedikt Leichtle; Uta Ceglarek; Peter Weinert; Christos T Nakas; Jean-Marc Nuoffer; Julia Kase; Tim Conrad; Helmut Witzigmann; Joachim Thiery; Georg Martin Fiedler
Journal:  Metabolomics       Date:  2012-11-06       Impact factor: 4.290

5.  PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Chih-Horng Wu; Xin-Jia Chen; Ting-Chun Kuo; Shih-Hung Yang; I-Lun Shih; Hong-Shiee Lai; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

Review 6.  MRS-based Metabolomics in Cancer Research.

Authors:  Tedros Bezabeh; Omkar B Ijare; Alexander E Nikulin; Rajmund L Somorjai; Ian Cp Smith
Journal:  Magn Reson Insights       Date:  2014-02-13

7.  Plasma metabolite biomarkers for the detection of pancreatic cancer.

Authors:  Guoxiang Xie; Lingeng Lu; Yunping Qiu; Quanxing Ni; Wei Zhang; Yu-Tang Gao; Harvey A Risch; Herbert Yu; Wei Jia
Journal:  J Proteome Res       Date:  2014-12-08       Impact factor: 4.466

8.  Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats.

Authors:  Shi Wen; Zhishui Li; Jianghua Feng; Jianxi Bai; Xianchao Lin; Heguang Huang
Journal:  Cancer Sci       Date:  2016-05-17       Impact factor: 6.716

9.  Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.

Authors:  Takao Itoi; Masahiro Sugimoto; Junko Umeda; Atsushi Sofuni; Takayoshi Tsuchiya; Shujiro Tsuji; Reina Tanaka; Ryosuke Tonozuka; Mitsuyoshi Honjo; Fuminori Moriyasu; Kazuhiko Kasuya; Yuichi Nagakawa; Yuta Abe; Kimihiro Takano; Shigeyuki Kawachi; Motohide Shimazu; Tomoyoshi Soga; Masaru Tomita; Makoto Sunamura
Journal:  Int J Mol Sci       Date:  2017-04-04       Impact factor: 5.923

10.  Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.

Authors:  Khyati Y Mehta; Hung-Jen Wu; Smrithi S Menon; Yassi Fallah; Xiaogang Zhong; Nasser Rizk; Keith Unger; Mark Mapstone; Massimo S Fiandaca; Howard J Federoff; Amrita K Cheema
Journal:  Oncotarget       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.